Title: Prevalence of H. Pylori in Inflammatory Bowel Disease Patients and its Association with
Severity
Version: 3 Date: 05 Mar 2025
Reviewer's report:
It is a decent observational study, although there has been enough data on this aspect.
The following are suggested to enhance the manuscript:
1. STROBE guidelines to be followed and the same be mentioned in the methods section
2. The results need a better description
3. The discussion needs to be augmented. The following maybe discussed and referenced:
a. Bretto E, Frara S, Armandi A, Caviglia GP, Saracco GM, Bugianesi E, Pitoni D, Ribaldone
DG. Helicobacter pylori in Inflammatory Bowel Diseases: Active Protagonist or Innocent
Bystander? Antibiotics (Basel). 2024 Mar 17;13(3):267. doi: 10.3390/antibiotics13030267.
PMID: 38534702; PMCID: PMC10967592.
b. Ding ZH, Xu XP, Wang TR, Liang X, Ran ZH, Lu H. The prevalence of Helicobacter
pylori infection in inflammatory bowel disease in China: A case-control study. PLoS One.
2021 Mar 12;16(3):e0248427. doi: 10.1371/journal.pone.0248427. PMID: 33711050; PMCID:
PMC7954320.
c. Ali I, Abdo Q, Al-Hihi SM, Shawabkeh A. Association between ulcerative colitis and
Helicobacter pylori infection: A case-control study. Heliyon. 2022 Feb 9;8(2):e08930. doi:
10.1016/j.heliyon.2022.e08930. PMID: 35198786; PMCID: PMC8841358.
d. Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease
and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-
analysis. Ann Gastroenterol. 2020 Sep-Oct;33(5):485-494. doi: 10.20524/aog.2020.0507. Epub
2020 Jun 6. PMID: 32879595; PMCID: PMC7406810.
4. The limitations of the study have not been mentioned. They are required as it is an
observational study
Title: Prevalence of H. Pylori in Inflammatory Bowel Disease Patients and its Association with
Severity
Version: 3 Date: 05 Mar 2025
Reviewer's report:
It is a decent observational study, although there has been enough data on this aspect.
The following are suggested to enhance the manuscript:
1. STROBE guidelines to be followed and the same be mentioned in the methods section
2. The results need a better description
3. The discussion needs to be augmented. The following maybe discussed and referenced:
a. Bretto E, Frara S, Armandi A, Caviglia GP, Saracco GM, Bugianesi E, Pitoni D, Ribaldone
DG. Helicobacter pylori in Inflammatory Bowel Diseases: Active Protagonist or Innocent
Bystander? Antibiotics (Basel). 2024 Mar 17;13(3):267. doi: 10.3390/antibiotics13030267.
PMID: 38534702; PMCID: PMC10967592.
b. Ding ZH, Xu XP, Wang TR, Liang X, Ran ZH, Lu H. The prevalence of Helicobacter
pylori infection in inflammatory bowel disease in China: A case-control study. PLoS One.
2021 Mar 12;16(3):e0248427. doi: 10.1371/journal.pone.0248427. PMID: 33711050; PMCID:
PMC7954320.
c. Ali I, Abdo Q, Al-Hihi SM, Shawabkeh A. Association between ulcerative colitis and
Helicobacter pylori infection: A case-control study. Heliyon. 2022 Feb 9;8(2):e08930. doi:
10.1016/j.heliyon.2022.e08930. PMID: 35198786; PMCID: PMC8841358.
d. Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease
and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-
analysis. Ann Gastroenterol. 2020 Sep-Oct;33(5):485-494. doi: 10.20524/aog.2020.0507. Epub
2020 Jun 6. PMID: 32879595; PMCID: PMC7406810.
4. The limitations of the study have not been mentioned. They are required as it is an
observational study
Please review this paper.
user
Title: Prevalence of H. Pylori in Inflammatory Bowel Disease Patients and its Association with
Severity
Version: 3 Date: 05 Mar 2025
Reviewer's report:
It is a decent observational study, although there has been enough data on this aspect.
The following are suggested to enhance the manuscript:
1. STROBE guidelines to be followed and the same be mentioned in the methods section
2. The results need a better description
3. The discussion needs to be augmented. The following maybe discussed and referenced:
a. Bretto E, Frara S, Armandi A, Caviglia GP, Saracco GM, Bugianesi E, Pitoni D, Ribaldone
DG. Helicobacter pylori in Inflammatory Bowel Diseases: Active Protagonist or Innocent
Bystander? Antibiotics (Basel). 2024 Mar 17;13(3):267. doi: 10.3390/antibiotics13030267.
PMID: 38534702; PMCID: PMC10967592.
b. Ding ZH, Xu XP, Wang TR, Liang X, Ran ZH, Lu H. The prevalence of Helicobacter
pylori infection in inflammatory bowel disease in China: A case-control study. PLoS One.
2021 Mar 12;16(3):e0248427. doi: 10.1371/journal.pone.0248427. PMID: 33711050; PMCID:
PMC7954320.
c. Ali I, Abdo Q, Al-Hihi SM, Shawabkeh A. Association between ulcerative colitis and
Helicobacter pylori infection: A case-control study. Heliyon. 2022 Feb 9;8(2):e08930. doi:
10.1016/j.heliyon.2022.e08930. PMID: 35198786; PMCID: PMC8841358.
d. Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease
and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-
analysis. Ann Gastroenterol. 2020 Sep-Oct;33(5):485-494. doi: 10.20524/aog.2020.0507. Epub
2020 Jun 6. PMID: 32879595; PMCID: PMC7406810.
4. The limitations of the study have not been mentioned. They are required as it is an
observational study
assistant